| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection BF Keele, EE Giorgi, JF Salazar-Gonzalez, JM Decker, KT Pham, ... Proceedings of the National Academy of Sciences 105 (21), 7552-7557, 2008 | 2379 | 2008 |
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial BF Haynes, PB Gilbert, MJ McElrath, S Zolla-Pazner, GD Tomaras, ... New England Journal of Medicine 366 (14), 1275-1286, 2012 | 2158 | 2012 |
| The immune response during acute HIV-1 infection: clues for vaccine development AJ McMichael, P Borrow, GD Tomaras, N Goonetilleke, BF Haynes Nature Reviews Immunology 10 (1), 11-23, 2010 | 1199 | 2010 |
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies … GD Tomaras, NL Yates, P Liu, L Qin, GG Fouda, LL Chavez, AC Decamp, ... Journal of virology 82 (24), 12449-12463, 2008 | 858 | 2008 |
| Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine SM Hammer, ME Sobieszczyk, H Janes, ST Karuna, MJ Mulligan, ... New England Journal of Medicine 369 (22), 2083-2092, 2013 | 718 | 2013 |
| Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors M Bonsignori, KK Hwang, X Chen, CY Tsao, L Morris, E Gray, DJ Marshall, ... Journal of virology 85 (19), 9998-10009, 2011 | 520 | 2011 |
| Combination therapy with anti-HIV-1 antibodies maintains viral suppression P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler, K Millard, ... Nature 561 (7724), 479-484, 2018 | 514 | 2018 |
| Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination NL Yates, HX Liao, Y Fong, A DeCamp, NA Vandergrift, WT Williams, ... Science translational medicine 6 (228), 228ra39-228ra39, 2014 | 492 | 2014 |
| Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG GD Tomaras, G Ferrari, X Shen, SM Alam, HX Liao, J Pollara, ... Proceedings of the National Academy of Sciences 110 (22), 9019-9024, 2013 | 466 | 2013 |
| Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2 HX Liao, M Bonsignori, SM Alam, JS McLellan, GD Tomaras, MA Moody, ... Immunity 38 (1), 176-186, 2013 | 452 | 2013 |
| Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family M Bonsignori, J Pollara, MA Moody, MD Alpert, X Chen, KK Hwang, ... Journal of virology 86 (21), 11521-11532, 2012 | 452 | 2012 |
| Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers O Lambotte, G Ferrari, C Moog, NL Yates, HX Liao, RJ Parks, CB Hicks, ... Aids 23 (8), 897-906, 2009 | 423 | 2009 |
| Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C JM Binley, EA Lybarger, ET Crooks, MS Seaman, E Gray, KL Davis, ... Journal of virology 82 (23), 11651-11668, 2008 | 422 | 2008 |
| CD4 T follicular helper cell dynamics during SIV infection C Petrovas, T Yamamoto, MY Gerner, KL Boswell, K Wloka, EC Smith, ... The Journal of clinical investigation 122 (9), 3281-3294, 2012 | 378 | 2012 |
| Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) DH Barouch, FL Tomaka, F Wegmann, DJ Stieh, G Alter, ML Robb, ... The Lancet 392 (10143), 232-243, 2018 | 354 | 2018 |
| CXCL13 is a plasma biomarker of germinal center activity C Havenar-Daughton, M Lindqvist, A Heit, JE Wu, SM Reiss, K Kendric, ... Proceedings of the National Academy of Sciences 113 (10), 2702-2707, 2016 | 351 | 2016 |
| Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study KM Hastie, H Li, D Bedinger, SL Schendel, SM Dennison, K Li, ... Science 374 (6566), 472-478, 2021 | 312 | 2021 |
| Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection S Zolla-Pazner, A DeCamp, PB Gilbert, C Williams, NL Yates, ... PloS one 9 (2), e87572, 2014 | 302 | 2014 |
| COMPASS identifies T-cell subsets correlated with clinical outcomes L Lin, G Finak, K Ushey, C Seshadri, TR Hawn, N Frahm, TJ Scriba, ... Nature biotechnology 33 (6), 610-616, 2015 | 288 | 2015 |
| An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and … G Ferrari, J Pollara, D Kozink, T Harms, M Drinker, S Freel, MA Moody, ... Journal of virology 85 (14), 7029-7036, 2011 | 281 | 2011 |
David C Montefiori, Ph.D.Duke University Medical Centerยืนยันอีเมลแล้วที่ duke.edu